Academic Journals Database
Disseminating quality controlled scientific knowledge

Current Status and Future Direction of Multi-targeted Drugs 
in the Era of Personalized Therapy
—Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer

Author(s): Caicun ZHOU

Journal: Chinese Journal of Lung Cancer
ISSN 1009-3419

Volume: 14;
Issue: 11;
Start page: 874;
Date: 2011;
Original page

Keywords: Lung neoplasms | Multi-targeted tyrosine kinase inhibitor | Sunitinib | Sorafenib | Vandetanib | Crizotinib

Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase III studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC..
Save time & money - Smart Internet Solutions      Why do you need a reservation system?